Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.

Varghese AM, Arora A, Capanu M, Camacho N, Won HH, Zehir A, Gao J, Chakravarty D, Schultz N, Klimstra DS, Ladanyi M, Hyman DM, Solit DB, Berger MF, Saltz LB.

Ann Oncol. 2017 Dec 1;28(12):3015-3021. doi: 10.1093/annonc/mdx545.


Overview of various techniques/platforms with critical evaluation of each.

Agwa E, Ma PC.

Curr Treat Options Oncol. 2013 Dec;14(4):623-33. doi: 10.1007/s11864-013-0259-z. Review.


Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.

Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, Erlich RL, Rankin AN, Ali SM, Elvin JA, Morosini D, Miller VA, Stephens PJ.

JAMA Oncol. 2015 Apr;1(1):40-9. doi: 10.1001/jamaoncol.2014.216.


Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.

Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R.

Cancer Res. 2017 Aug 15;77(16):4238-4246. doi: 10.1158/0008-5472.CAN-17-0628. Epub 2017 Jun 22.


Molecular driver alterations and their clinical relevance in cancer of unknown primary site.

Löffler H, Pfarr N, Kriegsmann M, Endris V, Hielscher T, Lohneis P, Folprecht G, Stenzinger A, Dietel M, Weichert W, Krämer A.

Oncotarget. 2016 Jul 12;7(28):44322-44329. doi: 10.18632/oncotarget.10035.


Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.

Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, Fellowes A, Semple T, Fox S, Byron K, Kowalczyk A, Thomas D, Schofield P, Bowtell DD.

J Pathol. 2013 Dec;231(4):413-23. doi: 10.1002/path.4251.


Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.

Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA.

J Clin Oncol. 2013 Jan 10;31(2):217-23. doi: 10.1200/JCO.2012.43.3755. Epub 2012 Oct 1.


Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.

Gröschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C, Horak P, Fröhlich M, Uhrig S, Hübschmann D, Geörg C, Richter D, Pfarr N, Pfütze K, Wolf S, Schirmacher P, Jäger D, von Kalle C, Brors B, Glimm H, Weichert W, Stenzinger A, Fröhling S.

Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001180.


Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.

Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL.

Genome Med. 2016 Dec 23;8(1):133. doi: 10.1186/s13073-016-0389-6.


Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.

Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, Peled N.

J Thorac Oncol. 2017 Feb;12(2):258-268. doi: 10.1016/j.jtho.2016.10.021. Epub 2016 Nov 16.


Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.

Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC.

Oncotarget. 2017 Jan 31;8(5):7989-7998. doi: 10.18632/oncotarget.14008.


New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.

Varadhachary G.

Clin Cancer Res. 2013 Aug 1;19(15):4027-33. doi: 10.1158/1078-0432.CCR-12-3030. Epub 2013 Mar 21.


A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L.

Oncologist. 2014 May;19(5):453-8. doi: 10.1634/theoncologist.2013-0377. Epub 2014 Apr 7.


The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.

Fumagalli C, Vacirca D, Rappa A, Passaro A, Guarize J, Rafaniello Raviele P, de Marinis F, Spaggiari L, Casadio C, Viale G, Barberis M, Guerini-Rocco E.

J Clin Pathol. 2018 Sep;71(9):767-773. doi: 10.1136/jclinpath-2018-205032. Epub 2018 Mar 13.


Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.

Binder C, Matthes KL, Korol D, Rohrmann S, Moch H.

Cancer Med. 2018 Sep;7(9):4814-4824. doi: 10.1002/cam4.1689. Epub 2018 Jul 17.


Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.

Andersson C, Fagman H, Hansson M, Enlund F.

Cancer Genet. 2016 Apr;209(4):154-60. doi: 10.1016/j.cancergen.2016.02.004. Epub 2016 Feb 15.


A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.

Hainsworth JD, Schnabel CA, Erlander MG, Haines DW 3rd, Greco FA.

Clin Colorectal Cancer. 2012 Jun;11(2):112-8. doi: 10.1016/j.clcc.2011.08.001. Epub 2011 Oct 14.


Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.

Greco FA, Lennington WJ, Spigel DR, Hainsworth JD.

J Natl Cancer Inst. 2013 Jun 5;105(11):782-90. doi: 10.1093/jnci/djt099. Epub 2013 May 2.


Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL.

Genome Med. 2016 Oct 25;8(1):109.


Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.

Greco FA, Lennington WJ, Spigel DR, Hainsworth JD.

Mol Diagn Ther. 2015 Apr;19(2):91-7. doi: 10.1007/s40291-015-0133-8.


Supplemental Content

Support Center